Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.

George SH, Milea A, Shaw PA.

Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.

2.

A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.

Cass I, Walts AE, Barbuto D, Lester J, Karlan B.

Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.

PMID:
25026639
3.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
4.

Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.

Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.

Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.

PMID:
22710074
5.

Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma.

Tone AA, Virtanen C, Shaw PA, Brown TJ.

Endocr Relat Cancer. 2011 Feb 23;18(2):221-34. doi: 10.1530/ERC-10-0235. Print 2011 Apr.

6.

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.

Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.

PMID:
22921157
7.

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.

Clin Cancer Res. 2008 Jul 1;14(13):4067-78. doi: 10.1158/1078-0432.CCR-07-4959.

8.

Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.

George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA.

J Pathol. 2011 Sep;225(1):106-17. doi: 10.1002/path.2927. Epub 2011 Jul 8.

PMID:
21744340
9.

Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H.

Mod Pathol. 2009 Sep;22(9):1133-8. doi: 10.1038/modpathol.2009.89. Epub 2009 Jun 19.

10.

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.

Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.

BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.

11.

Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.

Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B.

Int J Gynecol Pathol. 2004 Jan;23(1):35-40.

PMID:
14668548
12.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP.

J Pathol. 2007 Jan;211(1):26-35. Erratum in: J Pathol. 2007 Sep;213(1):116.

PMID:
17117391
13.

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM.

Neoplasia. 2010 Dec;12(12):993-1002.

14.

Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.

Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.

PMID:
24681744
15.
16.

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY.

Obstet Gynecol. 2005 Dec;106(6):1327-34.

PMID:
16319259
17.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.

PMID:
20452659
18.

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP.

Am J Surg Pathol. 2006 Feb;30(2):230-6.

PMID:
16434898
19.

The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM.

Cancer. 2010 Nov 15;116(22):5261-71. doi: 10.1002/cncr.25439.

20.

Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Sehdev AS, Shih IeM.

Int J Gynecol Pathol. 2012 Sep;31(5):416-22. doi: 10.1097/PGP.0b013e31824cbeb4.

Items per page

Supplemental Content

Write to the Help Desk